Felicia D Goodrum Sterling, PhD

Associate Professor, Immunobiology
Associate Professor, BIO5 Institute
Director, Graduate Program in Immunobiology
Associate Professor, Cellular and Molecular Medicine
Associate Professor, Cancer Biology - GIDP
Associate Professor, Genetics - GIDP
Associate Professor, Molecular and Cellular Biology
Phone Number: 
(520) 626-7468
FAX: 
(520) 626-2100

UACC Information

UACC Organizational Unit(s): 
Professional Bio: 

Felicia Goodrum graduated with her PhD from Wake Forest University and then trained as a postdoctoral fellow with Thomas Shenk at Princeton University where she was a Leukemia and Lymphoma Society Fellow and Special Fellow. Dr. Goodrum joined the faculty at the University of Arizona in the Department of Immunobiology and the BIO5 Institute in 2006 and is an Assoicate Professor. Dr. Goodrum is the recipient of the Pew Scholar in Biomedical Sciences Award and the Presidential Award for Early Career Scientists and Engineers. Dr. Goodrum's work throughout her career has focused on complex interaction between viruses and their host and is currently focused on the mechanisms of viral persistence of human cytomegalovirus

Dr. Goodrum's long-standing research focus is to understand the molecular virus-host interactions important to human cytomegalovirus (CMV) latency and persistence in the host. While the molecular basis of CMV latency is poorly understood, it is critical to controlling CMV pathology in the immunocompromised, as well as pathologies (e.g. CMV disease following stem cell transplantation in leukemia patients) that are linked to persistence of the virus in healthy individuals. She has developed a physiologically-relevant, in vitro model for the study of HCMV latency using primary CD34+ hematopoietic progenitor cells (HPCs). Using this model, she has investigated the affects of HCMV on hematopoiesis and defined profiles of viral gene expression in defined CD34+ hematopoietic subpopulations.

As a PI on several NIH-funded grants, Dr. Goodrum has further identified the first virus-coded determinants required for HCMV latency and reactivation from latency. Their recent work has defined the epidermal growth factor receptor (EGFR) as primary pathway targeted by these viral determinants to switch between latent and replicative states of infection. The goal of their research program is to define the mechanistic underpinnings of HCMV latency and lay the foundation for clinical interventions to control CMV disease in all settings.

Research Information

Research Program: 
Cancer Biology
Member Status: 
Research Member
Year of Membership Acceptance: 
2005

Professional Information

Positions and Honors: 
Jamie McNew Endowed Lecturer - University of Minnesota, Spring 2014
Distinguished Speaker - Wake Forest University, Spring 2013
Robert Honess Lecturer - American Society of Virology, Spring 2012
Top 25 Reviewers - Journal of Virology, Spring 2012
Priscilla A. Schaffer Lecturship - Priscilla A. Schaffer Fund, Spring 2010
Kavli Fellow - National Academy of Sciences, Spring 2009
Top 20 Reviewers - Journal of Virology, Spring 2009
Junior Faculty International Conference Travel Award - University of Arizona, Spring 2008
Pew Scholar in Biomedical Sciences - Pew Charitable Trust, Spring 2008
Young Investigator Award - Human Frontiers in Science Program, Spring 2008
Howard Temin Career Development Award - National Cancer Institute, Spring 2005
Leukemia and Lymphoma Society, Special Fellow - Leukemia and Lymphoma Society, Spring 2003
Leukemia and Lymphoma Society, Fellow - Leukemia and Lymphoma Society, Spring 2000

Academic Information

Doctorate: 
Molecular Genetics, Wake Forest University School of Medicine, Winston-Salem, NC
Undergraduate School: 
BS, Biology, Virginia Tech, Blacksburg, VA